Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome
Status:
Completed
Trial end date:
2016-11-16
Target enrollment:
Participant gender:
Summary
The study is a randomized, double-blind, placebo-controlled study in children with Alagille
Syndrome (ALGS). The study will investigate the effects of LUM001, compared to placebo, on
pruritus, serum bile acids, liver enzymes, and other biochemical markers in patients with
ALGS.
Phase:
Phase 2
Details
Lead Sponsor:
Mirum Pharmaceuticals, Inc. Shire
Collaborator:
Childhood Liver Disease Research and Education Network